Fungal apocalypse: The emergence of drug-resistant Candida auris in the United States | ||
| Microbes and Infectious Diseases | ||
| Articles in Press, Accepted Manuscript, Available Online from 26 August 2024 | ||
| Document Type: Letter to the Editor | ||
| DOI: 10.21608/mid.2024.302586.2059 | ||
| Authors | ||
| Safayet Jamil* 1; Victor Abiola Adepoju2; ABM Alauddin Chowdhury3 | ||
| 1Department of Public Health, Daffodil International University, Dhaka 1216, Bangladesh | ||
| 2Department of HIV and Infectious Diseases, Jhpiego, an affiliate of John Hopkins University, Abuja, Nigeria | ||
| 3Department of Public health, Daffodil International University, Dhaka 1216, Bangladesh | ||
| Abstract | ||
| The discovery of a drug-resistant super fungus, Candida auris (C. auris), in Mississippi, United States, has raised concerns about its potential health risks. C. auris is a highly contagious fungus that is resistant to multiple antifungal drugs and can cause severe illnesses, including sepsis and meningitis, leading to death in those already treated for multiple health conditions. The fungus has high mortality rates, especially among those with underlying comorbidities like cancer and diabetes. The US Centers for Disease Control and Prevention has classified C. auris as an emerging global health threat. Most cases of C. auris in the US result from local spread within and among healthcare facilities in the same city or state. The fungus is difficult to identify with standard laboratory methods and poses a significant threat in terms of potential spread and transmission. The government and health authorities are urged to take immediate action, including increasing funding for research, developing new treatments, and implementing strict guidelines for healthcare facilities. | ||
| Keywords | ||
| Fungal Apocalypse; Drug-Resistant; Candida auris; Fungus infection; Antifungal | ||
|
Statistics Article View: 119 |
||
